Experimental disease models for the assessment of meningococcal vaccines

被引:24
作者
Gorringe, AR
Reddin, KM
Funnella, SG
Johansson, L
Rytkönen, A
Jonsson, AB
机构
[1] Hlth Protect Agcy, Salisbury SP4 0JG, Wilts, England
[2] Karolinska Univ Hosp, Ctr Infect Med, Dept Med, SE-14186 Stockholm, Sweden
[3] Univ London Imperial Coll Sci Technol & Med, Ctr Microbiol & Infect, Dept Infect Dis, London SW7 2AZ, England
[4] Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden
关键词
infection model; vaccine assessment; Neisseria meningitidis;
D O I
10.1016/j.vaccine.2005.01.053
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Animal infection models are valuable for the development and preclinical assessment, of meningococcal vaccines in the absence of clear in vitro correlates of protection for protein-based serogroup B vaccines. It is only in animal models that interactions of the organism with the innate, Immoral and cellular immune systems can be assessed. However, humans are the only natural host for Neisseria meningitidis and there is no ideal disease model using laboratory animals that mimics the course of human disease. The two most widely used models are intraperitoneal (i.p.) infection of adult mice or infant rats. The mouse i.p. infection model requires an exogenous iron source (e.g. human transferrin) to obtain a lethal bacteraemic infection and can be used to assess both active and passive immunisation. The virulence of wild-type and knockout mutants can also be compared. i.p. infection of infant rats has been used to assess passive protection provided by sera raised against vaccine candidates or human vaccine sera. However, the duration of bacteraemia is short, mortality is low and active protection cannot be assessed. Recent developments using transgenic mice expressing human CD46 give hope that improved models will be developed. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2214 / 2217
页数:4
相关论文
共 8 条
[1]  
Gorringe AR, 2001, METH MOLEC MED, V66, P241, DOI 10.1385/1-59259-148-5:241
[2]   CD46 in meningococcal disease [J].
Johansson, L ;
Rytkönen, A ;
Bergman, P ;
Albiger, B ;
Källström, H ;
Hökfelt, T ;
Agerberth, B ;
Cattaneo, R ;
Jonsson, AB .
SCIENCE, 2003, 301 (5631) :373-375
[3]   DEMONSTRATION OF LIPOOLIGOSACCHARIDE IMMUNOTYPE AND CAPSULE AS VIRULENCE FACTORS FOR NEISSERIA-MENINGITIDIS USING AN INFANT MOUSE INTRANASAL INFECTION MODEL [J].
MACKINNON, FG ;
BORROW, R ;
GORRINGE, AR ;
FOX, AJ ;
JONES, DM ;
ROBINSON, A .
MICROBIAL PATHOGENESIS, 1993, 15 (05) :359-366
[4]   Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity [J].
Newcombe, J ;
Eales-Reynolds, L ;
Wootton, L ;
Gorringe, AR ;
Funnell, SGP ;
Taylor, SC ;
McFadden, JJ .
INFECTION AND IMMUNITY, 2004, 72 (01) :338-344
[5]   Neisseria lactamica protects against experimental meningococcal infection [J].
Oliver, KJ ;
Reddin, KM ;
Bracegirdle, P ;
Hudson, MJ ;
Borrow, R ;
Feavers, IM ;
Robinson, A ;
Cartwright, K ;
Gorringe, AR .
INFECTION AND IMMUNITY, 2002, 70 (07) :3621-3626
[6]   COMPARATIVE-EVALUATION OF POTENTIAL COMPONENTS FOR GROUP-B MENINGOCOCCAL VACCINE BY PASSIVE PROTECTION IN THE INFANT RAT AND INVITRO BACTERICIDAL ASSAY [J].
SAUKKONEN, K ;
LEINONEN, M ;
ABDILLAHI, H ;
POOLMAN, JT .
VACCINE, 1989, 7 (04) :325-328
[7]   The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci [J].
Toropainen, M ;
Käyhty, H ;
Saarinen, L ;
Rosenqvist, E ;
Hoiby, EA ;
Wedege, E ;
Michaelsen, T ;
Mäkelä, PH .
VACCINE, 1999, 17 (20-21) :2677-2689
[8]   Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity [J].
Welsch, JA ;
Moe, GR ;
Rossi, R ;
Adu-Bobie, J ;
Rappuoli, R ;
Granoff, DM .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (11) :1730-1740